GSK
3 years ago ⋅ English ⋅ 2 min read
Newsroom
GSK tops Access to Medicine Index (ATMI) for eighth consecutive time

Company also announces £100 million investment over next ten years to support health system strengthening and access initiatives in lower income countriesGSK ranks 1st in the 2022... Read More
GSK
3 years ago ⋅ English ⋅ 5 min read
Newsroom
GSK announces positive Phase IIa study results for a new first-in-class candidate medicine for patients with tuberculosis

For media and investors only- GSK3036656 demonstrated early bactericidal activity with a low, once-daily oral dose after 14 days of treatment in participants with drug-susceptible pulmo... Read More
GSK
3 years ago ⋅ English ⋅ 2 min read
Newsroom
GSK provides an update on Zejula (niraparib) US prescribing information

For media and investors onlyGSK plc (LSE/NYSE: GSK) today provided an update that at the request of the US Food and Drug Administration (FDA) it will restrict the second-line maintenanc... Read More
GSK
3 years ago ⋅ English ⋅ 6 min read
Newsroom
Positive data for bepirovirsen from B-Clear phase IIb trial presented at American Association for the Study of Liver Diseases’ Meeting with simultaneous publication in the New England Journal of Medicine

For media and investors only- Phase III trial evaluating bepirovirsen to start in H1 2023- Phase II trials ongoing to explore potential sequential treatment options with the aim of incr... Read More
GSK
3 years ago ⋅ English ⋅ 4 min read
Newsroom
GSK provides update on DREAMM-3 phase III trial for Blenrep in relapsed/refractory multiple myeloma

For media and investors onlyGSK plc (LSE/NYSE: GSK) today announced that DREAMM-3, the phase III open-label, randomised head-to-head superiority trial of Blenrep (belantamab mafodotin)... Read More
GSK
3 years ago ⋅ English ⋅ 5 min read
Newsroom
EAGLE-2 and EAGLE-3 phase III trials for gepotidacin stopped early for efficacy following pre-planned interim analysis by Independent Data Monitoring Committee

For media and investors only- Gepotidacin could be the first new novel oral antibiotic treatment for uncomplicated urinary tract infections in over 20 years- GSK plans to submit a New D... Read More